Business
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S. Abecma collaboration with Bristol Myers Squibb’s (BMS)50.01M49.82%
Collaboration with Regeneron21.59M21.51%
ide-cel ex-U.S. service revenue from Bristol Myers Squibb’s (BMS)14.75M14.69%
Service revenue from December 2021 agreement with Novo Nordisk5.77M5.74%
Royalty and other revenue4.64M4.62%
Other3.63M3.61%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States100.39M100.00%
